Add BrightSurf on Google Email

American Society of Clinical Oncology


Chemotherapy given directly to the liver improves survival for patients with colorectal cancer

Researchers found that hepatic arterial infusion (HAI) therapy extended survival and improved quality of life in patients with colorectal cancer that has spread to the liver. HAI therapy resulted in a median survival of 24 months, better response rates, and longer time to disease progression compared to systemic chemotherapy.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateFeb 27, 2006

History of smoking significantly reduces survival in head and neck cancer patients

A study published in the Journal of Clinical Oncology found that smokers have a higher risk of death, disease recurrence, and poorer survival rates compared to non-smokers with head and neck cancer. Researchers highlighted the importance of tobacco cessation and moderation of alcohol use to improve quality of life and survival.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateSep 29, 2004

Group therapy does not improve survival In early-stage breast cancer patients

A recent study found that group therapy did not improve survival rates in early-stage breast cancer patients. The researchers, led by David W. Kissane, evaluated the impact of cognitive-existential group therapy (CEGT) on survival and found no significant difference between those receiving CEGT and those not receiving it.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateSep 27, 2004

ASCO releases new technology assessment

The American Society of Clinical Oncology (ASCO) has released a new technology assessment recommending against the use of chemotherapy sensitivity and resistance assays. The assessment found limitations in the literature, including small sample sizes and low yield of assays, cast doubt on their effectiveness in determining treatment.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateAug 2, 2004

Extended lymph node dissection fails to increase long-term survival among gastric cancer patients

A study published in Journal of Clinical Oncology found that extended lymph node dissection does not increase long-term survival among gastric cancer patients, potentially increasing morbidity and hospital mortality. The procedure may only be beneficial if safe and effective alternatives can be developed.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateApr 12, 2004

Liver transplants result in excellent survival rates for patients with liver cancer

A US study found that liver transplantation significantly improves five-year survival rates for patients with hepatocellular carcinoma (HCC), from 25.3% in the late 1980s to 61.1% in the early 2000s. The study suggests that careful patient selection based on improved criteria may be a key factor in these improvements.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateOct 27, 2003

New studies demonstrate importance of offering range of treatment options to elderly cancer patients

Two new studies found that elderly lung cancer patients benefit equally from aggressive chemotherapy and radiation treatment, contradicting common assumptions. Fit elderly patients should be fully briefed on treatment options, including potential risks and benefits. The studies suggest presenting the full range of treatment options to ...

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateAug 28, 2003

Newer lung cancer treatments extend survival longer than traditional regimens

This study found that paclitaxel- and carboplatin-based regimens can prolong survival of patients with advanced non-small cell lung cancer, with two-year survival rates similar to those achieved at one year with best supportive care. However, three-drug regimens were slightly more toxic and did not provide additional benefits.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateJun 27, 2002

New chemotherapy regimen produces long-term, disease-free survival in patients with uncommon, aggressive types of lymphoma, leukemia

Researchers found that brief cycles of high-dose chemotherapy produced long-term disease-free survival in more than half of adults treated for Burkitt's small non-cleaved lymphoma and leukemia. The regimen achieved an 80% complete response rate, with 52% of patients remaining in continuous remission after five years.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateOct 11, 2001